Reporter Xiao Feng.
On May 9, 2023, Jilin Zixin Pharmaceutical Co., Ltd. *** abbreviation: *ST Zixin; **002118) announced that its controlling shareholder, Sinopharm Zhaoxiang (Changchun) Pharmaceutical, received the "Notice of Case Filing" (No. 0202023003 Zheng Jian Case Filing) issued by the China ** Regulatory Commission (hereinafter referred to as the "China Securities Regulatory Commission"). Due to the suspected trading of Zixin Pharmaceutical during the restricted period, in accordance with the "Law of the People's Republic of China", "Administrative Punishment Law of the People's Republic of China" and other laws and regulations, the China Securities Regulatory Commission decided to file a case against Sinopharm Zhaoxiang (Changchun) Pharmaceutical. A few days ago, the Hengcai Insurance team has received the "Pre-litigation Mediation Letter" from the Changchun Intermediate People's Court.
Lawyer Pang (TZ315-WH) of the 315 team of Hengcai Bao Weiheng Financial said that the injured investors who preliminarily judged that during the period from February 17, 2015 to January 6, 2023 (inclusive), and sold or still held the ** after January 7, 2023, can file a claim (the final claim conditions are subject to the court's determination).
Zixin Pharmaceutical was terminated from listing.
On January 6, 2023, Zixin Pharmaceutical announced that the company and Mr. Guo Chunsheng, the former actual controller of the company, recently received the "Notice of Case Filing" (No. 0202023001 Zheng Jian Case No. ) (No. 0202023002 Zheng Jian Case Filing) issued by the China Securities Regulatory Commission. Due to suspected violations of laws and regulations in information disclosure, in accordance with the "** Law of the People's Republic of China", "Administrative Punishment Law of the People's Republic of China" and other laws and regulations, the China Securities Regulatory Commission decided to file a case against the company and Guo Chunsheng.
On June 21, 2023, Zixin Pharmaceutical received the "Prior Notice" issued by the Shenzhen ** Stock Exchange (Company Department Letter No. 210 of 2023), which reads as follows: "From May 19, 2023 to June 15, 2023, the daily ** price of the company ** through the trading system of the Exchange for 20 consecutive trading days was lower than 1 yuan, touching Article 9 of the ** Listing Rules of the Exchange2.In the case of ** termination of listing as stipulated in Item (4) of Paragraph 1 of Article 1, the Exchange intends to decide to terminate the listing transaction of your company. ”
At present, Zixin Pharmaceutical's claim is ongoing, and the injured shareholders can contact the 315 team of Hengcai Bao Weiheng Finance (TZ315-WH) to consult whether the claim conditions and procedures are met.